Cynapsus Therapeutics Announces Successful Completion of Bioavailability and Pharmacokinetic Study and Provides Update on European Clinical Plans Dec 10, 2021
Cynapsus Therapeutics Announces Positive Data Presentations at World Congress on Parkinson's Disease and Related Disorders Meeting Dec 8, 2021
Cynapsus Therapeutics Reports Third Quarter 2015 Financial Results and Recent Developments Nov 12, 2021
Cynapsus Therapeutics Enrolls First Patient in Pivotal Phase 3 Safety Study of APL-130277 for the Treatment of OFF Episodes in Patients With Parkinson's Disease Sep 2, 2021
Cynapsus Therapeutics Reports Second Quarter 2015 Financial Results and Recent Developments Aug 14, 2021
Cynapsus Therapeutics' APL-130277 Improved Parkinson's Symptoms and Rapidly Turned Patients from OFF to ON Jun 25, 2022
